Following a full submission
AWMSG advice |
|||
| Status: Not recommended | |||
Rosuvastatin (Crestor®) is not recommended for use within NHS Wales for the prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors. The clinical and cost effectiveness evidence provided was not sufficient for AWMSG to recommend its use. |
|||
|
|||
Medicine details |
|||
| Medicine name | rosuvastatin (Crestor®) | ||
| Formulation | film-coated tablet | ||
| Reference number | 679 | ||
| Indication | Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors |
||
| Company | AstraZeneca UK Ltd | ||
| BNF chapter | Cardiovascular system | ||
| Submission type | Full | ||
| Status | Not recommended | ||
| Advice number | 1311 | ||
| NMG meeting date | 05/10/2011 | ||
| AWMSG meeting date | 09/11/2011 | ||
| Ratification by Welsh Government | 17/01/2012 | ||
| Date of issue | 17/01/2012 | ||